Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Persistent Losses • Negative Cash Burn HTFL's strong balance sheet and low debt are offset by persistent losses, negative free cash flow, and a demanding valuation, making the stock hard to justify on current fundamentals.
Price Behavior
Key Price Behavior Insights: • Breakout above resistance • Stretched momentum • Volatility risk Support Level: $27.25-$27.30; deeper support $25.20-$25.60 Resistance Level: $28.82 Over the last month, HTFL broke above prior resistance near $27.25-$27.30 and remains in a short-term uptrend, but the fast move from $25.23 leaves it stretched and vulnerable to a pullback if support fails.
Sentiment & News
Key News Insights: • Product expansion • Billing code • CEO sale HeartFlow's AI diagnostics platform is gaining commercial traction through validated Plaque Analysis and an expected billing code, but the CEO's recent share sale adds a cautionary insider signal for investors.
AI Summary
HTFL has moved from a promising AI diagnostics story to a real commercialization/reimbursement inflection, where Plaque Analysis and billing-code expansion could unlock repeatable revenue, but the investment now hinges on payer adoption translating into operating leverage because losses, cash burn, and a demanding valuation leave little room for execution misses.
Description
HeartFlow offers a non-invasive diagnostic platform that converts a single coronary CT angiogram into a patient-specific 3D heart model and applies computational fluid dynamics and related analytics to quantify blood flow, arterial narrowing, and plaque characteristics. Founded in 2007 and based in Mountain View, California, the company distributes its technology globally to support clinical assessment and management of coronary artery disease.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 23 | Mar 30 | HTFL | Heartflow, Inc. Common Stock | HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses. | Closed | -11.0% |